prikaz prve stranice dokumenta Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab
  Preuzmi
PDF 693.27 KB
Znanstveni rad - Prikaz slučaja
Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab
Acta Clinica Belgica, 75 (2020), 5; 357-361. https://doi.org/10.1080/17843286.2019.1608395
Krečak, Ivan; Medić Grgić, Marijana; Gverić–Krečak, Velka; Rončevć, Pavle; Bašić Kinda, Sandra; Babel, Jaksa; Radonić, Radovan

Citirajte ovaj rad

Krečak, I., Medić Grgić, M., Gverić–Krečak, V., Rončevć, P., Bašić Kinda, S., Babel, J. i Radonić, R. (2020). Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. Acta Clinica Belgica, 75. (5), 357-361. doi: 10.1080/17843286.2019.1608395

Krečak, Ivan, et al. "Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab." Acta Clinica Belgica, vol. 75, br. 5, 2020, str. 357-361. https://doi.org/10.1080/17843286.2019.1608395

Krečak, Ivan, Marijana Medić Grgić, Velka Gverić–Krečak, Pavle Rončevć, Sandra Bašić Kinda, Jaksa Babel i Radovan Radonić. "Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab." Acta Clinica Belgica 75, br. 5 (2020): 357-361. https://doi.org/10.1080/17843286.2019.1608395

Krečak, I., et al. (2020) 'Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab', Acta Clinica Belgica, 75(5), str. 357-361. doi: 10.1080/17843286.2019.1608395

Krečak I, Medić Grgić M, Gverić–Krečak V, Rončevć P, Bašić Kinda S, Babel J, i sur.. Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. Acta Clinica Belgica [Internet]. 10.2020. [pristupljeno 14.04.2024.];75(5):357-361. doi: 10.1080/17843286.2019.1608395

I. Krečak, et al., "Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab", Acta Clinica Belgica, vol. 75, br. 5, str. 357-361, Listopad 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:253954. [Citirano: 14.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:253954
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab
AutorIvan Krečak
AutorMarijana Medić Grgić
AutorVelka Gverić–Krečak
AutorPavle Rončevć
AutorSandra Bašić Kinda
AutorJaksa Babel
AutorRadovan Radonić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). In this paper, we describe the first case of CMML with auto-antibodies to ADAMTS13, presenting initially as plasmapheresis-refractory Coombs-positive aTTP. ----- Results: Although our patient was not treated for CMML, a complete remission of aTTP was eventually achieved with rituximab. Conclusion; We propose that aTTP should be in the differential diagnosis of CMML patients with thrombocytopenia and anemia (Coombs positive or not) who develop signs of thrombotic microangiopathy. Further studies are much needed to decipher the immune-mediated processes in CMML.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaActa Clinica Belgica
Brojčani podacivol. 75, br. 5, str. 357-361
p-ISSN1784-3286
e-ISSN2295-3337
DOIhttps://doi.org/10.1080/17843286.2019.1608395
URN:NBNurn:nbn:hr:105:253954
Datum objave publikacije2020-10
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/17843286.2019.1608395
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Datum isteka embarga: 2021-11-01
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-01-28 10:22:42